Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial

Eur Respir J. 2022 Mar 10;59(3):2103036. doi: 10.1183/13993003.03036-2021. Print 2022 Mar.

Abstract

The addition of inhaled budesonide to usual care is safe and may reduce the risk of disease progression in patients hospitalised because of COVID-19 pneumonia https://bit.ly/3tEQo3p

Trial registration: ClinicalTrials.gov NCT04355637.

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Administration, Inhalation
  • Bronchodilator Agents / therapeutic use
  • Budesonide*
  • COVID-19*
  • Double-Blind Method
  • Glucocorticoids / therapeutic use
  • Humans
  • SARS-CoV-2

Substances

  • Bronchodilator Agents
  • Glucocorticoids
  • Budesonide

Associated data

  • ClinicalTrials.gov/NCT04355637